MIRAMAR BEACH, Fla.--(BUSINESS WIRE)--A Texas Medical Center research team has made a stunning breakthrough in breast cancer research using revolutionary 3D bioprinting technology being marketed and developed by Nano3D Biosciences (n3D), a joint venture partner of Rainbow Coral Corp. (OTCBB:RBCC).
Researchers were able to create a better in vitro model of breast cancer by magnetically levitating cells using n3D’s Bio-Assembler, part of the world’s first commercially available 3D bioprinting system designed for high throughput and high-content drug screening. By magnetically levitating cell cultures, the research team was able to replicate in vitro the cell heterogeneity of the tumor microenvironment.
“These results signify a crucial breakthrough in studying cancer cells outside the body and developing new treatments. We at n3D are very proud that the Bio-Assembler, a technology we developed, is being used in critical research such as this important study,” said Dr. Glauco Souza, n3D president and chief science officer, and a co-author of the study, which was published in Scientific Reports, a top 5 multidisciplinary science primary research journal.
In the study, entitled “Three Dimensional In Vitro Co-Culture Model of Breast Tumor Using Magnetic Levitation,” research data suggests “that the proposed 3D in vitro breast tumor is advantageous due to the ability to: (1) form large-sized (millimeter in diameter) breast tumor models within 24 h; (2) control tumor cell composition and density; (3) accurately mimic the in vivo tumor microenvironment; and (4) test drug efficiency in an in vitro model that is comparable to in vivo tumors.”
For months, RBCC and n3D have been focused on raising millions of dollars to further market and develop 3D bioprinting technology around the globe.
“The Bio-Assembler uses biocompatible magnetic nanoparticles to levitate cells, allowing them to grow into 3D structures much faster, easier and more affordably than competing technology currently on the market,” said RBCC CEO Kimberly Palmer. “This cutting-edge study by the team in Texas perfectly shows why the Bio-Assembler is a technology coveted by leading scientists across a variety of disciplines and beautifully illustrates how it’s pushing cellular research forward.”
READ MORE ABOUT THE STUDY: http://www.nature.com/srep/2014/141001/srep06468/full/srep06468.html
VIEW FIGURES AND IMAGES: http://www.nature.com/srep/2014/141001/srep06468/fig_tab/srep06468_ft.html
About Rainbow Biosciences
Rainbow Biosciences, LLC, a wholly owned biotech subsidiary of Rainbow Coral Corp. (OTCBB:RBCC), was formed to deliver new medical and research technology innovations to a global marketplace in order to compete alongside companies such as Biogen Idec Inc. (NASDAQ:BIIB), Abbott Laboratories (NYSE:ABT) and Amgen Inc. (NASDAQ:AMGN). The Company continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. In 2012, Rainbow Biosciences acquired an equity interest in n3D. For more information on our growth-oriented business initiatives, please visit www.RainbowBioSciences.com. For investment information and performance data on the Company, please visit www.RainbowBioSciences.com/investors.html.
Notice Regarding Forward-Looking Statements
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words "believes," "expects," "anticipate" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from those expressed or implied by such forward-looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release speaks as of the date first set forth above and the Company assumes no responsibility to update the information included herein for events occurring after the date hereof.